Keyphrases
Single-arm Study
100%
Evolution Study
100%
Advanced Hepatocellular Carcinoma
100%
Ramucirumab
100%
Lenvatinib
85%
Atezolizumab Plus Bevacizumab
71%
Adverse Events
42%
Japan
14%
Hypertension
14%
Number of Patients
14%
Discontinuation Rate
14%
Overall Survival
14%
Proteinuria
14%
Systemic Therapy
14%
Median Progression-free Survival
14%
Progression-free Survival
14%
Neutropenia
14%
Multicenter Prospective Study
14%
Second-line Treatment
14%
Prior Treatment
14%
Third-line Treatment
14%
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Arm
100%
Ramucirumab
100%
Lenvatinib
85%
Bevacizumab
71%
Atezolizumab
71%
Adverse Event
42%
Progression Free Survival
28%
Survival Rate
14%
Overall Survival
14%
Prospective Study
14%
Proteinuria
14%
Systemic Therapy
14%
Neutropenia
14%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Ramucirumab
100%
Lenvatinib
85%
Bevacizumab
71%
Atezolizumab
71%
Adverse Event
42%
Progression Free Survival
28%
Prospective Study
14%
Survival Rate
14%
Proteinuria
14%
Overall Survival
14%
Neutropenia
14%